Form 483

Guilin Pharmaceutical Co., Ltd. Form 483, 2023-08-18

FDA issued a Form 483 to Guilin Pharmaceutical Co., Ltd. on 2023-08-18 with 12 public-safe observations.

483· Form 483 issuedHuman Drugs12 observations

Guilin Pharmaceutical Co., Ltd. · Guilin, China · Issued August 18, 2023

Overview

  • 12 public-safe observations are available for this inspection.
  • 4 structured CFR citations are represented.
  • 2 investigators are tied to this Form 483.

Inspectional observations

Each observation cites the regulation FDA found the firm out of compliance with.

18 Aug 2023
21 CFR 211.22(d)

Procedures not in writing, fully followed

Cited by Hung H Do, Rowena S Nguyen

18 Aug 2023
21 CFR 211.22(d)

Procedures not in writing, fully followed

Cited by Hung H Do, Rowena S Nguyen

18 Aug 2023
21 CFR 211.22(d)

Procedures not in writing, fully followed

Cited by Hung H Do, Rowena S Nguyen

18 Aug 2023
21 CFR 211.56(a)

Sanitation--buildings not clean, free of infestation

Cited by Hung H Do, Rowena S Nguyen

18 Aug 2023
21 CFR 211.56(a)

Sanitation--buildings not clean, free of infestation

Cited by Hung H Do, Rowena S Nguyen

Inspected site

Inspection team

Cited regulations

CFR citations associated with this Form 483.

CitationWhat it coversCited
21 CFR 211.22(d)Cited across public-safe Form 483 observations3x
21 CFR 211.56(a)Cited across public-safe Form 483 observations3x
21 CFR 211.63Cited across public-safe Form 483 observations3x
21 CFR 211.68(b)Cited across public-safe Form 483 observations3x

Full 483 report

Get the verbatim text of all 12 observations

The full inspection record, as Atlas holds it, so your team sees exactly what was cited and how it was answered.

  • The site's full inspection history around this Form 483
  • Whether these citations escalated to a warning letter
  • The investigators involved and the citations they repeat elsewhere